<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34677606</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>01</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1460-2156</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>Mar</Month><Day>29</Day></PubDate></JournalIssue><Title>Brain : a journal of neurology</Title><ISOAbbreviation>Brain</ISOAbbreviation></Journal><ArticleTitle>Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.</ArticleTitle><Pagination><StartPage>27</StartPage><EndPage>44</EndPage><MedlinePgn>27-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/brain/awab404</ELocationID><Abstract><AbstractText>Significant progress has been made in understanding the pre-symptomatic phase of amyotrophic lateral sclerosis. While much is still unknown, advances in other neurodegenerative diseases offer valuable insights. Indeed, it is increasingly clear that the well-recognized clinical syndromes of Alzheimer's disease, Parkinson's disease, Huntington's disease, spinal muscular atrophy and frontotemporal dementia are also each preceded by a pre-symptomatic or prodromal period of varying duration, during which the underlying disease process unfolds, with associated compensatory changes and loss of inherent system redundancy. Key insights from these diseases highlight opportunities for discovery in amyotrophic lateral sclerosis. The development of biomarkers reflecting amyloid and tau has led to a shift in defining Alzheimer's disease based on inferred underlying histopathology. Parkinson's disease is unique among neurodegenerative diseases in the number and diversity of non-genetic biomarkers of pre-symptomatic disease, most notably REM sleep behaviour disorder. Huntington's disease benefits from an ability to predict the likely timing of clinically manifest disease based on age and CAG-repeat length alongside reliable neuroimaging markers of atrophy. Spinal muscular atrophy clinical trials have highlighted the transformational value of early therapeutic intervention, and studies in frontotemporal dementia illustrate the differential role of biomarkers based on genotype. Similar advances in amyotrophic lateral sclerosis would transform our understanding of key events in pathogenesis, thereby dramatically accelerating progress towards disease prevention. Deciphering the biology of pre-symptomatic amyotrophic lateral sclerosis relies on a clear conceptual framework for defining the earliest stages of disease. Clinically manifest amyotrophic lateral sclerosis may emerge abruptly, especially among those who harbour genetic mutations associated with rapidly progressive amyotrophic lateral sclerosis. However, the disease may also evolve more gradually, revealing a prodromal period of mild motor impairment preceding phenoconversion to clinically manifest disease. Similarly, cognitive and behavioural impairment, when present, may emerge gradually, evolving through a prodromal period of mild cognitive impairment or mild behavioural impairment before progression to amyotrophic lateral sclerosis. Biomarkers are critically important to studying pre-symptomatic amyotrophic lateral sclerosis and essential to efforts to intervene therapeutically before clinically manifest disease emerges. The use of non-genetic biomarkers, however, presents challenges related to counselling, informed consent, communication of results and limited protections afforded by existing legislation. Experiences from pre-symptomatic genetic testing and counselling, and the legal protections against discrimination based on genetic data, may serve as a guide. Building on what we have learned-more broadly from other pre-symptomatic neurodegenerative diseases and specifically from amyotrophic lateral sclerosis gene mutation carriers-we present a road map to early intervention, and perhaps even disease prevention, for all forms of amyotrophic lateral sclerosis.</AbstractText><CopyrightInformation>&#xa9; The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4241-5135</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wuu</LastName><ForeName>Joanne</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McHutchison</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0103-8580</Identifier><AffiliationInfo><Affiliation>Human Cognitive Neuroscience, Department of Psychology, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Postuma</LastName><ForeName>Ronald B</ForeName><Initials>RB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Montreal Neurological Institute, McGill University, Montreal, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley F</ForeName><Initials>BF</Initials><Identifier Source="ORCID">0000-0002-4153-8187</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Mayo Clinic, Rochester, MN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ross</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0003-1882-5847</Identifier><AffiliationInfo><Affiliation>Division of Neurobiology, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arias</LastName><ForeName>Jalayne J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of California San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fradette</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Biogen, Cambridge, MA, 02142, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDermott</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Computational Biology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stanislaw</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-5191-6479</Identifier><AffiliationInfo><Affiliation>Department of Human Genetics, Emory University, Atlanta, GA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abrahams</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Human Cognitive Neuroscience, Department of Psychology, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Euan MacDonald Centre for MND Research, University of Edinburgh, Edinburgh, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosentino</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Psychiatry, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0003-0094-5429</Identifier><AffiliationInfo><Affiliation>Department of Clinical Science, Neurosciences, Ume&#xe5; University, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Finkel</LastName><ForeName>Richard S</ForeName><Initials>RS</Initials><AffiliationInfo><Affiliation>Department of Pediatric Medicine, Center for Experimental Neurotherapeutics, St. Jude Children's Research Hospital, Memphis, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Granit</LastName><ForeName>Volkan</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-6519-7225</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grignon</LastName><ForeName>Anne-Laure</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Miami, Miami, FL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><AffiliationInfo><Affiliation>Department of Neurodegenerative Disease, Dementia Research Centre, UCL Institute of Neurology, Queen Square, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McMillan</LastName><ForeName>Corey T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, King's College Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0000-0003-0267-3180</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>First International Pre-Symptomatic ALS Workshop</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K24 AG045333</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS086452</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS092091</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>TURNER/OCT18/989-797</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/M008525/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/T046015/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>P30 AG062677</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS105479</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/J009482/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>U01 AG006786</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P01 AG019724</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>MR/M023664/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-TALBOT/APR14/926-794</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>TURNER/JAN13/944-795</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600974</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Brain</MedlineTA><NlmUniqueID>0372537</NlmUniqueID><ISSNLinking>0006-8950</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Brain. 2022 Jul 29;145(7):2247-2249</RefSource><PMID Version="1">35429273</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058070" MajorTopicYN="N">Asymptomatic Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019636" MajorTopicYN="Y">Neurodegenerative Diseases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">disease prevention</Keyword><Keyword MajorTopicYN="N">neurodegeneration</Keyword><Keyword MajorTopicYN="N">pre-symptomatic</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Arias</LastName><ForeName>Jalayne</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Benatar</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boeve</LastName><ForeName>Bradley</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cosentino</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dave</LastName><ForeName>Kuldip</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Toby</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Floeter</LastName><ForeName>Mary-Kay</ForeName><Initials>MK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rohrer</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fradette</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gendron</LastName><ForeName>Tania</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Granit</LastName><ForeName>Volkan</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grignon</LastName><ForeName>Anne-Laure</ForeName><Initials>AL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grossman</LastName><ForeName>Murray</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gubitz</LastName><ForeName>Amelie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Petra</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Ber</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Suzee</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malaspina</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McDermott</LastName><ForeName>Michael P</ForeName><Initials>MP</Initials></Investigator><Investigator ValidYN="Y"><LastName>McHutchison</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>McMillan</LastName><ForeName>Corey</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicholson</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Petersen</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Postuma</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosen</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ross</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shefner</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stanislaw</LastName><ForeName>Christine</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tatton</LastName><ForeName>Nadine</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thakur</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turner</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weishaupt</LastName><ForeName>Jochen</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wuu</LastName><ForeName>Joanne</ForeName><Initials>J</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>6</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>22</Day><Hour>12</Hour><Minute>21</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34677606</ArticleId><ArticleId IdType="pmc">PMC8967095</ArticleId><ArticleId IdType="doi">10.1093/brain/awab404</ArticleId><ArticleId IdType="pii">6408437</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Duara R, Loewenstein DA, Greig MT, et al. . Pre-MCI and MCI: Neuropsychological, clinical, and imaging features and progression rates. Am J Geriatr Psychiatry. 2011;19(11):951&#x2013;960.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175279</ArticleId><ArticleId IdType="pubmed">21422909</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Amariglio RE, Buckley RF, et al. . The characterisation of subjective cognitive decline. Lancet Neurol. 2020;19(3):271&#x2013;278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7062546</ArticleId><ArticleId IdType="pubmed">31958406</ArticleId></ArticleIdList></Reference><Reference><Citation>Jessen F, Amariglio RE, van Boxtel M, et al. ; Subjective Cognitive Decline Initiative (SCD-I) Working Group. A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease. Alzheimers Dement. 2014;10(6):844&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4317324</ArticleId><ArticleId IdType="pubmed">24798886</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabin LA, Smart CM, Amariglio RE.. Subjective cognitive decline in preclinical Alzheimer's disease. Annu Rev Clin Psychol. 2017;13:369&#x2013;396.</Citation><ArticleIdList><ArticleId IdType="pubmed">28482688</ArticleId></ArticleIdList></Reference><Reference><Citation>van Harten AC, Mielke MM, Swenson-Dravis DM, et al. . Subjective cognitive decline and risk of MCI: The Mayo Clinic Study of Aging. Neurology. 2018;91(4):e300&#x2013;e312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6070384</ArticleId><ArticleId IdType="pubmed">29959257</ArticleId></ArticleIdList></Reference><Reference><Citation>Cacace R, Sleegers K, Van Broeckhoven C.. Molecular genetics of early-onset Alzheimer's disease revisited. Alzheimers Dement. 2016;12(6):733&#x2013;748.</Citation><ArticleIdList><ArticleId IdType="pubmed">27016693</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM.. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34(7):939&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">6610841</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256(3):183&#x2013;194.</Citation><ArticleIdList><ArticleId IdType="pubmed">15324362</ArticleId></ArticleIdList></Reference><Reference><Citation>Gillis C, Mirzaei F, Potashman M, Ikram MA, Maserejian N.. The incidence of mild cognitive impairment: A systematic review and data synthesis. Alzheimers Dement (Amst). 2019;11:248&#x2013;256.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6416157</ArticleId><ArticleId IdType="pubmed">30911599</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC, Lopez O, Armstrong MJ, et al. . Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(3):126&#x2013;135.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5772157</ArticleId><ArticleId IdType="pubmed">29282327</ArticleId></ArticleIdList></Reference><Reference><Citation>van Maurik IS, van der Kall LM, de Wilde A, et al. ; Alzheimer's Disease Neuroimaging Initiative. Added value of amyloid PET in individualized risk predictions for MCI patients. Alzheimers Dement (Amst). 2019;11(1):529&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6667768</ArticleId><ArticleId IdType="pubmed">31388557</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. ; Contributors. NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimers Dementia. 2018;14(4):535&#x2013;562.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5958625</ArticleId><ArticleId IdType="pubmed">29653606</ArticleId></ArticleIdList></Reference><Reference><Citation>Jack CR Jr, Bennett DA, Blennow K, et al. . A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. Neurology. 2016;87(5):539&#x2013;547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4970664</ArticleId><ArticleId IdType="pubmed">27371494</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks J, Syrjanen J, Graff-Radford J, et al. Comparison of neurofialment light and total tau as blood-based biomarkers of neurodegeneration: Associations with cognition and neuroimaging outcomes. In: 2021 Annual Meeting. American Academy of Neurology; 2021.</Citation></Reference><Reference><Citation>Preische O, Schultz SA, Apel A, et al. ; Dominantly Inherited Alzheimer Network. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer's disease. Nat Med. 2019;25(2):277&#x2013;283.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6367005</ArticleId><ArticleId IdType="pubmed">30664784</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017 Wartenberg lecture. Neurology. 2018;91(9):395&#x2013;402.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6133623</ArticleId><ArticleId IdType="pubmed">30089620</ArticleId></ArticleIdList></Reference><Reference><Citation>Mintun MA, Lo AC, Duggan Evans C, et al. . Donanemab in early Alzheimer's disease. New Engl J Med. 2021;384(18):1691&#x2013;1704.</Citation><ArticleIdList><ArticleId IdType="pubmed">33720637</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinovici GD. Controversy and progress in Alzheimer's disease&#x2014;FDA approval of aducanumab. New Engl J Med. 2021;385(9):771&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">34320284</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn B, Stein P, Cavazzoni P.. Approval of aducanumab for Alzheimer disease&#x2014;the FDA's perspective. JAMA Intern Med. 2021;181(10):1276.</Citation><ArticleIdList><ArticleId IdType="pubmed">34254984</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Aducanumab: What about the patient? Ann Neurol. 2021;90(3):334&#x2013;335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8434994</ArticleId><ArticleId IdType="pubmed">34322904</ArticleId></ArticleIdList></Reference><Reference><Citation>Bateman RJ, Benzinger TL, Berry S, et al. ; DIAN-TU Pharma Consortium for the Dominantly Inherited Alzheimer Network. The DIAN-TU Next Generation Alzheimer's prevention trial: Adaptive design and disease progression model. Alzheimers Dement. 2017;13(1):8&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5218895</ArticleId><ArticleId IdType="pubmed">27583651</ArticleId></ArticleIdList></Reference><Reference><Citation>Sperling RA, Rentz DM, Johnson KA, et al. . The A4 study: Stopping AD before symptoms begin? Sci Transl Med. 2014;6(228):228fs213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4049292</ArticleId><ArticleId IdType="pubmed">24648338</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariot PN, Lopera F, Langbaum JB, et al. ; Alzheimer's Prevention Initiative. The Alzheimer's Prevention Initiative Autosomal-Dominant Alzheimer's Disease Trial: A study of crenezumab versus placebo in preclinical PSEN1 E280A mutation carriers to evaluate efficacy and safety in the treatment of autosomal-dominant Alzheimer's disease, including a placebo-treated noncarrier cohort. Alzheimers Dement (N Y). 2018;4:150&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6021543</ArticleId><ArticleId IdType="pubmed">29955659</ArticleId></ArticleIdList></Reference><Reference><Citation>Pringsheim T, Jette N, Frolkis A, Steeves TD.. The prevalence of Parkinson's disease: A systematic review and meta-analysis. Mov Disord. 2014;29(13):1583&#x2013;1590.</Citation><ArticleIdList><ArticleId IdType="pubmed">24976103</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuhlenbaumer G, Berg D.. Parkinson disease genetics: Too early to predict progression? Nat Rev Neurol. 2019;15(11):625&#x2013;626.</Citation><ArticleIdList><ArticleId IdType="pubmed">31534210</ArticleId></ArticleIdList></Reference><Reference><Citation>Poewe W, Seppi K, Tanner CM, et al. . Parkinson disease. Nat Rev Dis Primers. 2017;3:17013.</Citation><ArticleIdList><ArticleId IdType="pubmed">28332488</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinzel S, Berg D, Gasser T, et al. ; MDS Task Force on the Definition of Parkinson's Disease. Update of the MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2019;34(10):1464&#x2013;1470.</Citation><ArticleIdList><ArticleId IdType="pubmed">31412427</ArticleId></ArticleIdList></Reference><Reference><Citation>Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB.. Evolution of prodromal Parkinson's disease and dementia with Lewy bodies: A prospective study. Brain. 2019;142(7):2051&#x2013;2067.</Citation><ArticleIdList><ArticleId IdType="pubmed">31111143</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Berg D.. Prodromal Parkinson's disease: The decade past, the decade to come. Mov Disord. 2019;34(5):665&#x2013;675.</Citation><ArticleIdList><ArticleId IdType="pubmed">30919499</ArticleId></ArticleIdList></Reference><Reference><Citation>Savica R, Carlin JM, Grossardt BR, et al. . Medical records documentation of constipation preceding Parkinson disease: A case-control study. Neurology. 2009;73(21):1752&#x2013;1758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2788809</ArticleId><ArticleId IdType="pubmed">19933976</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaufmann H, Norcliffe-Kaufmann L, Palma JA, et al. ; Autonomic Disorders Consortium. Natural history of pure autonomic failure: A United States prospective cohort. Ann Neurol. 2017;81(2):287&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5323269</ArticleId><ArticleId IdType="pubmed">28093795</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D, Godau J, Seppi K, et al. ; PRIPS study group. The PRIPS study: Screening battery for subjects at risk for Parkinson's disease. Eur J Neurol. 2013;20(1):102&#x2013;108.</Citation><ArticleIdList><ArticleId IdType="pubmed">22852790</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings D, Siderowf A, Stern M, et al. ; PARS Investigators. Conversion to Parkinson disease in the PARS hyposmic and dopamine transporter-deficit prodromal cohort. JAMA Neurol. 2017;74(8):933&#x2013;940.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5710321</ArticleId><ArticleId IdType="pubmed">28595287</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer W, Schmeichel AM, Shahnawaz M, et al. . Alpha-synuclein oligomers and neurofilament light chain in spinal fluid differentiate multiple system atrophy from Lewy body synucleinopathies. Ann Neurol. 2020;88(3):503&#x2013;512.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7719613</ArticleId><ArticleId IdType="pubmed">32557811</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, Iranzo A, Hu M, et al. . Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: A multicentre study. Brain. 2019;142(3):744&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6391615</ArticleId><ArticleId IdType="pubmed">30789229</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D, Postuma RB, Adler CH, et al. . MDS research criteria for prodromal Parkinson's disease. Mov Disord. 2015;30(12):1600&#x2013;1611.</Citation><ArticleIdList><ArticleId IdType="pubmed">26474317</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D, Postuma RB, Bloem B, et al. . Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease. Mov Disord. 2014;29(4):454&#x2013;462.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4204150</ArticleId><ArticleId IdType="pubmed">24619848</ArticleId></ArticleIdList></Reference><Reference><Citation>A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell. 1993;72(6):971&#x2013;983.</Citation><ArticleIdList><ArticleId IdType="pubmed">8458085</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, Aylward EH, Wild EJ, et al. . Huntington disease: Natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 2014;10(4):204&#x2013;216.</Citation><ArticleIdList><ArticleId IdType="pubmed">24614516</ArticleId></ArticleIdList></Reference><Reference><Citation>Huntington Study Group PHAROS Investigators. At risk for Huntington disease: The PHAROS (Prospective Huntington At Risk Observational Study) cohort enrolled. Arch Neurol. 2006;63(7):991&#x2013;996.</Citation><ArticleIdList><ArticleId IdType="pubmed">16831969</ArticleId></ArticleIdList></Reference><Reference><Citation>Biglan KM, Shoulson I, Kieburtz K, et al. ; The Huntington Study Group PHAROS Investigators. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for clinical trials. JAMA Neurol. 2016;73(1):102&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">26569098</ArticleId></ArticleIdList></Reference><Reference><Citation>Biglan KM, Ross CA, Langbehn DR, et al. . Motor abnormalities in premanifest persons with Huntington's disease: The PREDICT-HD study. Mov Disord. 2009;24(12):1763&#x2013;1772.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048804</ArticleId><ArticleId IdType="pubmed">19562761</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Hayden M, Stout JC, et al. ; Predict-HD Investigators of the Huntington Study Group. Preparing for preventive clinical trials: The Predict-HD study. Arch Neurol. 2006;63(6):883&#x2013;890.</Citation><ArticleIdList><ArticleId IdType="pubmed">16769871</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Langbehn DR, Stout JC, et al. ; Predict-HD Investigators and Coordinators of the Huntington Study Group. Detection of Huntington's disease decades before diagnosis: The Predict-HD study. J Neurol Neurosurg Psychiatry. 2008;79(8):874&#x2013;880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2569211</ArticleId><ArticleId IdType="pubmed">18096682</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild EJ, Tabrizi SJ.. Predict-HD and the future of therapeutic trials. Lancet Neurol. 2006;5(9):724&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914400</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, Langbehn DR, Leavitt BR, et al. . Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: Cross-sectional analysis of baseline data. Lancet Neurol. 2009;8(9):791&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3725974</ArticleId><ArticleId IdType="pubmed">19646924</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, Scahill RI, Durr A, et al. . Biological and clinical changes in premanifest and early stage Huntington's disease in the TRACK-HD study: The 12-month longitudinal analysis. Lancet Neurol. 2011;10(1):31&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">21130037</ArticleId></ArticleIdList></Reference><Reference><Citation>Unified Huntington's Disease Rating Scale: Reliability and consistency. Huntington Study Group. Mov Disord. 1996;11(2):136&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pubmed">8684382</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross CA, Reilmann R, Cardoso F, et al. . Movement Disorder Society Task Force Viewpoint: Huntington's disease diagnostic categories. Mov Disord Clin Pract. 2019;6(7):541&#x2013;546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6749806</ArticleId><ArticleId IdType="pubmed">31538087</ArticleId></ArticleIdList></Reference><Reference><Citation>Penney JB Jr, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH.. CAG repeat number governs the development rate of pathology in Huntington's disease. Ann Neurol. 1997;41(5):689&#x2013;692.</Citation><ArticleIdList><ArticleId IdType="pubmed">9153534</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Long JD, Mills JA, et al. ; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Indexing disease progression at study entry with individuals at-risk for Huntington disease. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(7):751&#x2013;763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3174494</ArticleId><ArticleId IdType="pubmed">21858921</ArticleId></ArticleIdList></Reference><Reference><Citation>Langbehn DR, Hayden MR, Paulsen JS.; and the PREDICT-HD Investigators of the Huntington Study Group. CAG-repeat length and the age of onset in Huntington disease (HD): A review and validation study of statistical approaches. Am J Med Genet B Neuropsychiatr Genet. 2010;153B(2):397&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3048807</ArticleId><ArticleId IdType="pubmed">19548255</ArticleId></ArticleIdList></Reference><Reference><Citation>Genetic Modifiers of Huntington&#x2019;s Disease (GeM-HD) Consortium. Identification of genetic factors that modify clinical onset of Huntington's disease. Cell. 2015;162(3):516&#x2013;526.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4524551</ArticleId><ArticleId IdType="pubmed">26232222</ArticleId></ArticleIdList></Reference><Reference><Citation>Aylward EH. Magnetic resonance imaging striatal volumes: A biomarker for clinical trials in Huntington's disease. Mov Disord. 2014;29(11):1429&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4479278</ArticleId><ArticleId IdType="pubmed">25164586</ArticleId></ArticleIdList></Reference><Reference><Citation>Paulsen JS, Long JD, Ross CA, et al. ; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Prediction of manifest Huntington's disease with clinical and imaging measures: A prospective observational study. Lancet Neurol. 2014;13(12):1193&#x2013;1201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4373455</ArticleId><ArticleId IdType="pubmed">25453459</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, Scahill RI, Owen G, et al. . Predictors of phenotypic progression and disease onset in premanifest and early-stage Huntington's disease in the TRACK-HD study: Analysis of 36-month observational data. Lancet Neurol. 2013;12(7):637&#x2013;649.</Citation><ArticleIdList><ArticleId IdType="pubmed">23664844</ArticleId></ArticleIdList></Reference><Reference><Citation>Aylward EH, Liu D, Nopoulos PC, et al. ; PREDICT-HD Investigators and Coordinators of the Huntington Study Group. Striatal volume contributes to the prediction of onset of Huntington disease in incident cases. Biol Psychiatry. 2012;71(9):822&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3237730</ArticleId><ArticleId IdType="pubmed">21907324</ArticleId></ArticleIdList></Reference><Reference><Citation>Southwell AL, Smith SE, Davis TR, et al. . Ultrasensitive measurement of huntingtin protein in cerebrospinal fluid demonstrates increase with Huntington disease stage and decrease following brain huntingtin suppression. Sci Rep. 2015;5:12166-</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4502413</ArticleId><ArticleId IdType="pubmed">26174131</ArticleId></ArticleIdList></Reference><Reference><Citation>Wild EJ, Boggio R, Langbehn D, et al. . Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients. J Clin Invest. 2015;125(5):1979&#x2013;1986.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4463213</ArticleId><ArticleId IdType="pubmed">25844897</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne LM, Rodrigues FB, Johnson EB, et al. . Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease. Sci Transl Med. 2018;10(458):eaat7108.</Citation><ArticleIdList><ArticleId IdType="pubmed">30209243</ArticleId></ArticleIdList></Reference><Reference><Citation>Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. ; Phase 1&#x2013;2a IONIS-HTTRx Study Site Teams. Targeting Huntingtin expression in patients with Huntington's disease. New Engl J Med. 2019;380(24):2307&#x2013;2316.</Citation><ArticleIdList><ArticleId IdType="pubmed">31059641</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrne LM, Rodrigues FB, Blennow K, et al. . Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: A retrospective cohort analysis. Lancet Neurol. 2017;16(8):601&#x2013;609.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5507767</ArticleId><ArticleId IdType="pubmed">28601473</ArticleId></ArticleIdList></Reference><Reference><Citation>Constantinescu R, Holmberg B, Rosengren L, Corneliusson O, Johnels B, Zetterberg H.. Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson's disease. Acta Neurol Scand. 2011;124(3):206&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">21039366</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemela V, Landtblom AM, Blennow K, Sundblom J.. Tau or neurofilament light&#x2014;which is the more suitable biomarker for Huntington's disease? PLoS ONE. 2017;12(2):e0172762.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5328385</ArticleId><ArticleId IdType="pubmed">28241046</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues FB, Byrne LM, Tortelli R, et al. . Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease. Sci Transl Med. 2020;12(574):eabc2888.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611886</ArticleId><ArticleId IdType="pubmed">33328328</ArticleId></ArticleIdList></Reference><Reference><Citation>Niemela V, Landtblom AM, Nyholm D, et al. . Proenkephalin decreases in cerebrospinal fluid with symptom progression of Huntington's disease. Mov Disord. 2021;36(2):481&#x2013;491.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7984171</ArticleId><ArticleId IdType="pubmed">33247616</ArticleId></ArticleIdList></Reference><Reference><Citation>Al Shweiki MR, Oeckl P, Pachollek A, et al. . Cerebrospinal fluid levels of prodynorphin-derived peptides are decreased in Huntington's disease. Mov Disord. 2021;36(2):492&#x2013;497.</Citation><ArticleIdList><ArticleId IdType="pubmed">33006791</ArticleId></ArticleIdList></Reference><Reference><Citation>Darras B, Monani U, De Vivo D.. Genetic disorders affecting the motor neuron: Spinal muscular atrophy. In: Swaiman K, Ashwal S, Ferriero D, et al. eds. Swaiman&#x2019;s pediatric neurology: Principles and practice. 6th edn.Elsevier; 2017:1057&#x2013;1064.</Citation></Reference><Reference><Citation>Lefebvre S, Burlet P, Liu Q, et al. . Correlation between severity and SMN protein level in spinal muscular atrophy. Nat Genet. 1997;16(3):265&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pubmed">9207792</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldkotter M, Schwarzer V, Wirth R, Wienker TF, Wirth B.. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Human Genet. 2002;70(2):358&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC419987</ArticleId><ArticleId IdType="pubmed">11791208</ArticleId></ArticleIdList></Reference><Reference><Citation>Swoboda KJ, Prior TW, Scott CB, et al. . Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005;57(5):704&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4334582</ArticleId><ArticleId IdType="pubmed">15852397</ArticleId></ArticleIdList></Reference><Reference><Citation>Mercuri E, Darras BT, Chiriboga CA, et al. . Nusinersen versus Sham control in later-onset spinal muscular atrophy. New Engl J Med. 2018;378(7):625&#x2013;635.</Citation><ArticleIdList><ArticleId IdType="pubmed">29443664</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS. Electrophysiological and motor function scale association in a pre-symptomatic infant with spinal muscular atrophy type I. Neuromuscul Disord. 2013;23(2):112&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">23146148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowes L, Alfano L, Chen D, et al. . Presymptomatic spinal muscular atrophy: Reality or myth? Neuromuscul Disord. 2019;29:S129.</Citation></Reference><Reference><Citation>Zerres K, Rudnik-Schoneborn S.. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch Neurol. 1995;52(5):518&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pubmed">7733848</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vivo DC, Bertini E, Swoboda KJ, et al. ; NURTURE Study Group. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul Disord. 2019;29(11):842&#x2013;856.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127286</ArticleId><ArticleId IdType="pubmed">31704158</ArticleId></ArticleIdList></Reference><Reference><Citation>
US National Library of Medicine. A Study of Risdiplam in Infants with Genetically Diagnosed and Presymptomatic Spinal Muscular Atrophy (Rainbowfish). Accessed May 2021. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03779334?term=NCT03779334&amp;draw=2&amp;rank=1</Citation></Reference><Reference><Citation>
US National Library of Medicine Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients with Multiple Copies of SMN2 (SPR1NT). Accessed May 2021. https://clinicaltrials.gov/ct2/show/NCT03505099?term=NCT03505099&amp;draw=2&amp;rank=1</Citation></Reference><Reference><Citation>Darras BT, Crawford TO, Finkel RS, et al. . Neurofilament as a potential biomarker for spinal muscular atrophy. Ann Clin Transl Neurol. 2019;6(5):932&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6530526</ArticleId><ArticleId IdType="pubmed">31139691</ArticleId></ArticleIdList></Reference><Reference><Citation>Dangouloff T, Servais L.. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: Current perspectives. Ther Clin Risk Manag. 2019;15:1153&#x2013;1161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6778729</ArticleId><ArticleId IdType="pubmed">31632042</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkel RS, Mercuri E, Darras BT, et al. . Nusinersen versus Sham Control in infantile-onset spinal muscular atrophy. New Engl J Med. 2017;377(18):1723&#x2013;1732.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091570</ArticleId></ArticleIdList></Reference><Reference><Citation>Day JW, Finkel RS, Chiriboga CA, et al. . Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): An open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol. 2021;20(4):284&#x2013;293.</Citation><ArticleIdList><ArticleId IdType="pubmed">33743238</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Al-Zaidy S, Shell R, et al. . Single-dose gene-replacement therapy for spinal muscular atrophy. New Engl J Med. 2017;377(18):1713&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Bang J, Spina S, Miller BL.. Frontotemporal dementia. Lancet. 2015;386(10004):1672&#x2013;1682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5970949</ArticleId><ArticleId IdType="pubmed">26595641</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Neumann M, Mackenzie IR.. Advances in understanding the molecular basis of frontotemporal dementia. Nat Rev Neurol. 2012;8(8):423&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3629543</ArticleId><ArticleId IdType="pubmed">22732773</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen HJ, Boeve BF, Boxer AL.. Tracking disease progression in familial and sporadic frontotemporal lobar degeneration: Recent findings from ARTFL and LEFFTDS. Alzheimers Dement. 2020;16(1):71&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6953606</ArticleId><ArticleId IdType="pubmed">31914219</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore KM, Nicholas J, Grossman M, et al. . Age at symptom onset and death and disease duration in genetic frontotemporal dementia: An international retrospective cohort study. Lancet Neurol. 2020;19(2):145&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7007771</ArticleId><ArticleId IdType="pubmed">31810826</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorno-Tempini ML, Hillis AE, Weintraub S, et al. . Classification of primary progressive aphasia and its variants. Neurology. 2011;76(11):1006&#x2013;1014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059138</ArticleId><ArticleId IdType="pubmed">21325651</ArticleId></ArticleIdList></Reference><Reference><Citation>Rascovsky K, Hodges JR, Knopman D, et al. . Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. Brain. 2011;134(Pt 9):2456&#x2013;2477.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170532</ArticleId><ArticleId IdType="pubmed">21810890</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen RC. Clinical practice. Mild cognitive impairment. New Engl J Med. 2011;364(23):2227&#x2013;2234.</Citation><ArticleIdList><ArticleId IdType="pubmed">21651394</ArticleId></ArticleIdList></Reference><Reference><Citation>Boeve B, Bove J, Brannelly P, et al. ; LEFFTDS Consortium. The longitudinal evaluation of familial frontotemporal dementia subjects protocol: Framework and methodology. Alzheimers Dement. 2020;16(1):22&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6949411</ArticleId><ArticleId IdType="pubmed">31636026</ArticleId></ArticleIdList></Reference><Reference><Citation>Olney NT, Ong E, Goh SM, et al. ; ARTFL and LEFFTDS consortia. Clinical and volumetric changes with increasing functional impairment in familial frontotemporal lobar degeneration. Alzheimers Dement. 2020;16(1):49&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6988137</ArticleId><ArticleId IdType="pubmed">31784375</ArticleId></ArticleIdList></Reference><Reference><Citation>Ismail Z, Smith EE, Geda Y, et al. ; ISTAART Neuropsychiatric Symptoms Professional Interest Area. Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers Dement. 2016;12(2):195&#x2013;202.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4684483</ArticleId><ArticleId IdType="pubmed">26096665</ArticleId></ArticleIdList></Reference><Reference><Citation>Rohrer JD, Nicholas JM, Cash DM, et al. . Presymptomatic cognitive and neuroanatomical changes in genetic frontotemporal dementia in the Genetic Frontotemporal dementia Initiative (GENFI) study: A cross-sectional analysis. Lancet Neurol. 2015;14(3):253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6742501</ArticleId><ArticleId IdType="pubmed">25662776</ArticleId></ArticleIdList></Reference><Reference><Citation>Thijssen EH, La Joie R, Wolf A, et al. ; Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators. Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387&#x2013;397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7101073</ArticleId><ArticleId IdType="pubmed">32123386</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Meeter LH, Poos JM, et al. . Serum neurofilament light chain in genetic frontotemporal dementia: A longitudinal, multicentre cohort study. Lancet Neurol. 2019;18(12):1103&#x2013;1111.</Citation><ArticleIdList><ArticleId IdType="pubmed">31701893</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Boeve BF, Schwarz CG, et al. ; LEFFTDS Consortium. Tracking white matter degeneration in asymptomatic and symptomatic MAPT mutation carriers. Neurobiol Aging. 2019;83:54&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6858933</ArticleId><ArticleId IdType="pubmed">31585367</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Boeve BF, Senjem M, et al. . Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: A longitudinal MRI study. Neurobiol Aging. 2020;88:42&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7767622</ArticleId><ArticleId IdType="pubmed">31918955</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Boeve BF, Senjem M, et al. ; LEFFTDS Consortium. Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimers Dement (N Y). 2019;5:338&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6675939</ArticleId><ArticleId IdType="pubmed">31388560</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Q, Boeve BF, Tosakulwong N, et al. . Brain MR spectroscopy changes precede frontotemporal lobar degeneration phenoconversion in Mapt mutation carriers. J Neuroimaging. 2019;29(5):624&#x2013;629.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6731148</ArticleId><ArticleId IdType="pubmed">31173437</ArticleId></ArticleIdList></Reference><Reference><Citation>Le Blanc G, Jette Pomerleau V, McCarthy J, et al. ; Genetic Frontotemporal Dementia Initiative (GENFI). Faster cortical thinning and surface area loss in presymptomatic and symptomatic C9orf72 repeat expansion adult carriers. Ann Neurol. 2020;88(1):113&#x2013;122.</Citation><ArticleIdList><ArticleId IdType="pubmed">32285980</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutsaerts H, Mirza SS, Petr J, et al. ; GENetic Frontotemporal dementia Initiative (GENFI). Cerebral perfusion changes in presymptomatic genetic frontotemporal dementia: A GENFI study. Brain. 2019;142(4):1108&#x2013;1120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439322</ArticleId><ArticleId IdType="pubmed">30847466</ArticleId></ArticleIdList></Reference><Reference><Citation>Staffaroni AM, Ljubenkov PA, Kornak J, et al. . Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials. Brain. 2019;142(2):443&#x2013;459.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6351779</ArticleId><ArticleId IdType="pubmed">30698757</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai RM, Bejanin A, Lesman-Segev O, et al. . F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. Alzheimers Res Ther. 2019;11(1):13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6357510</ArticleId><ArticleId IdType="pubmed">30704514</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones DT, Knopman DS, Graff-Radford J, et al. . In vivo (18)F-AV-1451 tau PET signal in MAPT mutation carriers varies by expected tau isoforms. Neurology. 2018;90(11):e947&#x2013;e954.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5858948</ArticleId><ArticleId IdType="pubmed">29440563</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Ende EL, Jackson JL, White A, Seelaar H, van Blitterswijk M, Van Swieten JC.. Unravelling the clinical spectrum and the role of repeat length in C9ORF72 repeat expansions. J Neurol Neurosurg Psychiatry. 2021;92(5):502&#x2013;509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8053328</ArticleId><ArticleId IdType="pubmed">33452054</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Turner MR, Wuu J.. Defining pre-symptomatic amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(5-6):303&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6613999</ArticleId><ArticleId IdType="pubmed">30892087</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner JM, Al-Chalabi A, Baker MR, et al. . A proposal for new diagnostic criteria for ALS. Clin Neurophysiol. 2020;131(8):1975&#x2013;1978.</Citation><ArticleIdList><ArticleId IdType="pubmed">32387049</ArticleId></ArticleIdList></Reference><Reference><Citation>Makki AA, Benatar M.. Diagnostic accuracy of thoracic paraspinal electromyography in amyotrophic lateral sclerosis. J Clin Neurophysiol. 2007;24(3):298&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">17545836</ArticleId></ArticleIdList></Reference><Reference><Citation>Makki AA, Benatar M.. The electromyographic diagnosis of amyotrophic lateral sclerosis: Does the evidence support the El Escorial criteria? Muscle Nerve. 2007;35(5):614&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">17294439</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Grace GM, Freedman M, et al. . Consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2009;10(3):131&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pubmed">19462523</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis D. Delis-Kaplan Executive Function System&#x2013;D-KEFS. The Psychological Corporation; 2001.</Citation></Reference><Reference><Citation>Heaton RK. Wisconsin Card Sorting Test Manual. Psychological assessment resources; 1981.</Citation></Reference><Reference><Citation>Kongs SK, Thompson LL, Iverson GL, Heaton RK.. Wisconsin Card Sorting Test-64 Card Version: WCST-64. PAR; 2000.</Citation></Reference><Reference><Citation>Kaplan EF, Goodglass H, Weintraub S.. The Boston Naming Test. 2nd ed. Lea and Febiger; 1983.</Citation></Reference><Reference><Citation>Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I.. The "Reading the Mind in the Eyes" Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry. 2001;42(2):241&#x2013;251.</Citation><ArticleIdList><ArticleId IdType="pubmed">11280420</ArticleId></ArticleIdList></Reference><Reference><Citation>Benton AL, deS K, Sivan AB.. Multilingual Aphasia Examination Third Edition. PAR Inc; 1994.</Citation></Reference><Reference><Citation>Benton AL, Varney NR, Hamsher KD.. Visuospatial judgment. A clinical test. Archives of Neurology. 1978;35(6):364&#x2013;367.</Citation><ArticleIdList><ArticleId IdType="pubmed">655909</ArticleId></ArticleIdList></Reference><Reference><Citation>Warrington EK, James M.. The Visual Object and Space Perception Battery: VOSP. Pearson; 1991.</Citation></Reference><Reference><Citation>Wechsler D. Wechsler Memory Scale (WMS-IV) technical and interpretive manual. Pearson; 2009.</Citation></Reference><Reference><Citation>Delis D, Kramer J, Kaplan E, Ober B.. California Verbal Learning Test: Adult Version Manual. The Psychological Corporation; 1987.</Citation></Reference><Reference><Citation>Raaphorst J, De Visser M, Linssen WHJP, De Haan RJ, Schmand B.. The cognitive profile of amyotrophic lateral sclerosis: A meta-analysis. Amyotroph Lateral Scler. 2010;11(1-2):27&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pubmed">19180349</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Leigh PN, Harvey A, Vythelingum GN, Gris&#xe9; D, Goldstein LH.. Verbal fluency and executive dysfunction in amyotrophic lateral sclerosis (ALS). Neuropsychologia. 2000;38(6):734&#x2013;747.</Citation><ArticleIdList><ArticleId IdType="pubmed">10689049</ArticleId></ArticleIdList></Reference><Reference><Citation>Gollan TH, Weissberger GH, Runnqvist E, Montoya RI, Cera CM.. Self-ratings of Spoken Language Dominance: A Multi-Lingual Naming Test (MINT) and Preliminary Norms for Young and Aging Spanish-English Bilinguals. Biling (Camb Engl). 2012;15(3):594&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4212892</ArticleId><ArticleId IdType="pubmed">25364296</ArticleId></ArticleIdList></Reference><Reference><Citation>Lomen-Hoerth C, Murphy J, Langmore S, Kramer JH, Olney RK, Miller B.. Are amyotrophic lateral sclerosis patients cognitively normal?. Neurology. 2003;60(7):1094&#x2013;1097.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682312</ArticleId></ArticleIdList></Reference><Reference><Citation>Possin KL, Laluz VR, Alcantar OZ, Miller BL, Kramer JH.. Distinct neuroanatomical substrates and cognitive mechanisms of figure copy performance in Alzheimer's disease and behavioral variant frontotemporal dementia. Neuropsychologia. 2011;49(1):43&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3005024</ArticleId><ArticleId IdType="pubmed">21029744</ArticleId></ArticleIdList></Reference><Reference><Citation>Pocock SJ. The combination of randomized and historical controls in clinical trials. J Chronic Dis. 1976;29(3):175&#x2013;188.</Citation><ArticleIdList><ArticleId IdType="pubmed">770493</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Stanislaw C, Reyes E, et al. . Presymptomatic ALS genetic counseling and testing: Experience and recommendations. Neurology. 2016;86(24):2295&#x2013;2302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4909562</ArticleId><ArticleId IdType="pubmed">27194384</ArticleId></ArticleIdList></Reference><Reference><Citation>Fanos JH, Gronka S, Wuu J, Stanislaw C, Andersen PM, Benatar M.. Impact of presymptomatic genetic testing for familial amyotrophic lateral sclerosis. Genet Med. 2011;13(4):342&#x2013;348.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4039017</ArticleId><ArticleId IdType="pubmed">21285887</ArticleId></ArticleIdList></Reference><Reference><Citation>United States Department of Labor. The Genetic Information Nondiscrimination Act of 2008 (GINA). In: US Department of Labor EBSA, ed. Public Law No. 110-233. Vol. H.R. 493. Washington, DC; 2008.</Citation></Reference><Reference><Citation>Prince AE, Berkman BE.. When does an illness begin: Genetic discrimination and disease manifestation. J Law Med Ethics. 2012;40(3):655&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4142506</ArticleId><ArticleId IdType="pubmed">23061591</ArticleId></ArticleIdList></Reference><Reference><Citation>Harkins K, Sankar P, Sperling R, et al. . Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants. Alzheimers Res Ther. 2015;7(1):26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4428104</ArticleId><ArticleId IdType="pubmed">25969699</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J.. Presymptomatic studies in ALS: Rationale, challenges, and approach. Neurology. 2012;79(16):1732&#x2013;1739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3468777</ArticleId><ArticleId IdType="pubmed">23071166</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Andersen P, et al. . Design of a Phase 3, randomized, placebo-controlled trial of Tofersen in clinically pre-symptomatic SOD1 mutation carriers: The ATLAS study. In: American Academy of Neurology Annual Meeting 2021. American Academy of Neurology; 2021.</Citation></Reference><Reference><Citation>Miller T, Cudkowicz M, Shaw PJ, et al. . Phase 1-2 trial of antisense oligonucleotide Tofersen for SOD1 ALS. New Engl J Med. 2020;383(2):109&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pubmed">32640130</ArticleId></ArticleIdList></Reference><Reference><Citation>Abrahams S, Newton J, Niven E, Foley J, Bak TH.. Screening for cognition and behaviour changes in ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(1-2):9&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">23781974</ArticleId></ArticleIdList></Reference><Reference><Citation>Crockford C, Kleynhans M, Wilton E, et al. . ECAS A-B-C: Alternate forms of the Edinburgh cognitive and behavioural ALS screen. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(1-2):57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">29205065</ArticleId></ArticleIdList></Reference><Reference><Citation>Niven E, Newton J, Foley J, et al. . Validation of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): A cognitive tool for motor disorders. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(3-4):172&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pubmed">25967542</ArticleId></ArticleIdList></Reference><Reference><Citation>Weintraub S, Besser L, Dodge HH, et al. . Version 3 of the Alzheimer Disease Centers&#x2019; neuropsychological test battery in the Uniform Data Set (UDS). Alzheimer Dis Assoc Disord. 2018;32(1):10&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5821520</ArticleId><ArticleId IdType="pubmed">29240561</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolley SC, York MK, Moore DH, et al. . Detecting frontotemporal dysfunction in ALS: Utility of the ALS Cognitive Behavioral Screen (ALS-CBS&#x2122;). Amyotroph Lateral Scler. 2010;11(3):303&#x2013;311.</Citation><ArticleIdList><ArticleId IdType="pubmed">20433413</ArticleId></ArticleIdList></Reference><Reference><Citation>Gavett BE, Ashendorf L, Gurnani AS.. Reliable change on neuropsychological tests in the Uniform Data Set. J Int Neuropsychol Soc. 2015;21(7):558&#x2013;567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4860819</ArticleId><ArticleId IdType="pubmed">26234918</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobson NS, Truax P.. Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol. 1991;59(1):12&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">2002127</ArticleId></ArticleIdList></Reference><Reference><Citation>McSweeny AJ, Naugle RI, Chelune GJ, L&#xfc;ders H.. &#x2018;T scores for change&#x2019;: An illustration of a regression approach to depicting change in clinical neuropsychology. Clin Neuropsychol. 1993;7(3):300&#x2013;312.</Citation></Reference><Reference><Citation>Duff K. Evidence-based indicators of neuropsychological change in the individual patient: Relevant concepts and methods. Arch Clin Neuropsychol. 2012;27(3):248&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3499091</ArticleId><ArticleId IdType="pubmed">22382384</ArticleId></ArticleIdList></Reference><Reference><Citation>Blair JR, Spreen O.. Predicting premorbid IQ: A revision of the National Adult Reading Test. Clin Neuropsychol. 1989;3(2):129&#x2013;136.</Citation></Reference><Reference><Citation>Pearson N. Advanced clinical solutions for WAIS-IV and WMS-IV: Administration and scoring manual. The Psychological Corporation; 2009.</Citation></Reference><Reference><Citation>Wechsler D. Test of premorbid functioning. UK version (TOPF UK). Pearson Corporation; 2011.</Citation></Reference><Reference><Citation>Barona A, Reynolds CR, Chastain R.. A demographically based index of premorbid intelligence for the WAIS&#x2014;R. J Consult Clin Psychol. 1984;52(5):885&#x2013;887.</Citation></Reference><Reference><Citation>Taylor MJ, Heaton RK.. Sensitivity and specificity of WAIS&#x2013;III/WMS&#x2013;III demographically corrected factor scores in neuropsychological assessment. J Int Neuropsychol Soc. 2001;7(7):867&#x2013;874.</Citation><ArticleIdList><ArticleId IdType="pubmed">11771630</ArticleId></ArticleIdList></Reference><Reference><Citation>Strong MJ, Abrahams S, Goldstein LH, et al. . Amyotrophic lateral sclerosis - frontotemporal spectrum disorder (ALS-FTSD): Revised diagnostic criteria. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(3-4):153&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7409990</ArticleId><ArticleId IdType="pubmed">28054827</ArticleId></ArticleIdList></Reference><Reference><Citation>Kertesz A, Davidson W, Fox H.. Frontal Behavioral Inventory: Diagnostic criteria for frontal lobe dementia. Can J Neurol Sci. 1997;24(1):29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">9043744</ArticleId></ArticleIdList></Reference><Reference><Citation>Wear HJ, Wedderburn CJ, Mioshi E, et al. . The Cambridge Behavioural Inventory Revised. Dement Neuropsychol. 2008;2(2):102&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5619578</ArticleId><ArticleId IdType="pubmed">29213551</ArticleId></ArticleIdList></Reference><Reference><Citation>Elamin M, Pinto-Grau M, Burke T, et al. . Identifying behavioural changes in ALS: Validation of the Beaumont Behavioural Inventory (BBI). Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(1-2):68&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">27894191</ArticleId></ArticleIdList></Reference><Reference><Citation>Grace J, Malloy PF.. Frontal systems behavior scale: FrSBe. Psychological Assessment Resources Lutz; 2001.</Citation></Reference><Reference><Citation>Benatar M, Wuu J, Andersen PM, Lombardi V, Malaspina A.. Neurofilament light: A candidate biomarker of pre-symptomatic ALS and phenoconversion. Ann Neurol. 2018;84(1):130&#x2013;139.</Citation><ArticleIdList><ArticleId IdType="pubmed">30014505</ArticleId></ArticleIdList></Reference><Reference><Citation>Benatar M, Wuu J, Lombardi V, et al. . Neurofilaments in pre-symptomatic ALS and the impact of genotype. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(7-8):538&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6768722</ArticleId><ArticleId IdType="pubmed">31432691</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghadessi M, Tang R, Zhou J, et al. . A roadmap to using historical controls in clinical trials - by Drug Information Association Adaptive Design Scientific Working Group (DIA-ADSWG). Orphanet J Rare Dis. 2020;15(1):69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7069184</ArticleId><ArticleId IdType="pubmed">32164754</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim J, Walley R, Yuan J, et al. . Minimizing patient burden through the use of historical subject-level data in innovative confirmatory clinical trials: Review of methods and opportunities. Ther Innov Regul Sci. 2018;52(5):546&#x2013;559.</Citation><ArticleIdList><ArticleId IdType="pubmed">29909645</ArticleId></ArticleIdList></Reference><Reference><Citation>Viele K, Berry S, Neuenschwander B, et al. . Use of historical control data for assessing treatment effects in clinical trials. Pharm Stat. 2014;13(1):41&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3951812</ArticleId><ArticleId IdType="pubmed">23913901</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>